GPE
HUTCHMED Withdraws Fruquintinib Application for Second-Line Gastric Cancer Treatment in China
HUTCHMED, fruquintinib, gastric cancer, second-line treatment, China, NDA withdrawal
ReNeuron Exits London Stock Exchange Amid Jacobio’s China Rights Deal
ReNeuron, Jacobio, London Stock Exchange, AIM, China rights deal, biotech, stem cell therapy
Duality Biotherapeutics Files for Hong Kong IPO, Expanding ADC Therapeutics Portfolio
Duality Biotherapeutics, Hong Kong IPO, ADC Therapeutics, BioNTech, BeiGene, Cancer Treatment
UCB Divests Chinese Production Plant and Older Medications for $680 Million
UCB, production plant, older medications, China, $680M, pharmaceutical industry, divestment
Jazz Pharmaceuticals’ Epidiolex Fails to Meet Primary Endpoint in Japanese Phase 3 Trial for Treatment-Resistant Epilepsies
Jazz Pharmaceuticals, Epidiolex, Cannabidiol Oral Solution, Treatment-Resistant Epilepsies, Phase 3 Trial, Japan
WuXi AppTec Unfazed by BIOSECURE Act Threat, Secures New US Deals
WuXi AppTec, BIOSECURE Act, US Deals, Pharmaceutical Manufacturing, Biotech Industry
Merck’s Ebola Vaccine Demonstrates 84% Effectiveness in Real-World Setting During DRC Outbreak
Ebola vaccine, Merck, Ervebo, effectiveness, real-world analysis, DRC outbreak, vaccination, public health.
Leqembi, Biogen and Eisai’s Alzheimer’s Drug, Gains UK Approval but Faces Cost-Effectiveness Hurdle
Leqembi, Alzheimer’s disease, UK approval, NICE, cost-effectiveness, Biogen, Eisai
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
TYK Medicines Secures $74M in Hong Kong IPO to Advance EGFR Cancer Therapy
TYK Medicines, IPO, EGFR cancer therapy, Hong Kong, biotech funding